CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
A clear look at the stablecoins that outperformed peers this year, with insights into drivers and risk considerations for future allocations.
26,211 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
June delivered a mix of headlines and price moves that kept traders on their toes. Robinhood’s 10% workforce cut alon...
Two Senate bills would let six-story apartment buildings use a single interior exit stair, a move that could lower co...
Greg Abel leads Berkshire Hathaway as the company holds a record cash pile. This in-depth guide explains what that me...
Fairway Home Mortgage launches a nonprofit arm to combat elder financial fraud, unveiling Fairway SAFE with free educ...
The Digital Chamber launches the Prediction Markets Working Group to win federal oversight for prediction markets, se...
Fiserv is a payments and tech-enabled services giant that faced headwinds. This in-depth look breaks down the challen...
Delaying Medicare enrollment can cost you more than you expect. This guide explains how missing this medicare deadlin...
A high-yield dividend stock jumped about 31% over three months. As March begins, investors must weigh income potentia...
Taiwan Semiconductor faces a 13% pullback that traders are weighing against its AI demand tailwinds and manufacturing...
CrowdStrike delivered a solid ARR beat but guided below lofty expectations, triggering a about 7% drop in CRWD shares...
Berkshire Hathaway just resumed stock buybacks after a long pause, signaling a shift in capital allocation. This arti...